NovaBay Says Its Avenova Cuts Bacteria On Ocular Skin Surface By Over 90%

NovaBay Pharmaceuticals, Inc. NBY revealed the presentation of clinical data demonstrating that its Avenova reduced the bacterial load on the ocular skin surface by over 90 percent in 20 minutes without affecting the diversity in the remaining bacteria type. According to the company, results of the Avenova study were already discussed in an oral presentation by its SVP of Ophthalmology Development, David Stroman, at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle.

NovaBay's VP of Sales and Marketing, Glenn Moro, commented, "In vitro and non-clinical studies have shown that in solution the bacteria and other microorganism that are a common underlying cause of chronic conditions such as blepharitis are killed. In fact, many patients suffering from the itchiness, inflammation and irritation associated with blepharitis and dry eye syndrome are reporting relief of symptoms in as little as two weeks with soothing Avenova used twice-daily."

Moro added, "That said, many ophthalmologists and optometrists are looking for clinical validation before prescribing Avenova to their patients. We now have that validation, giving us a clear advantage in a very large and underserved market."

On Monday, the stock shed 14.3 percent.